Avmapki (avutometinib) and Fakzynja (defactinib) are a combination approved in 2025 for low-grade serous ovarian cancer with a KRAS mutation, typically for those who've already had prior treatment. They work by targeting two different pathways that help this type of ovarian cancer grow.
Both are taken as pills, which is a Show Full Answer
Avmapki (avutometinib) and Fakzynja (defactinib) are a combination approved in 2025 for low-grade serous ovarian cancer with a KRAS mutation, typically for those who've already had prior treatment. They work by targeting two different pathways that help this type of ovarian cancer grow.
Both are taken as pills, which is a nice change from IV treatments!
The most commonly reported side effects include:
- Nausea
- Diarrhea
- Swelling
- Skin changes
- Tiredness/fatigue Since this combination was only approved in 2025, personal experiences shared within the community may still be limited. However, many of the side effects like nausea and fatigue are common across ovarian cancer treatments, and there are ways to manage them.
For nausea, eating smaller, more frequent meals and avoiding spicy or fried foods can help. For fatigue, gentle physical activity and good nutrition can make a difference. Always talk to your care team about any side effects — they can suggest medications or adjustments to help keep you as comfortable as possible.
May 12
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
